Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04751383
Title Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

osteosarcoma

neuroblastoma

Therapies

Dinutuximab + Hu5F9-G4

Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.